Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 13/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 13/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 13/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 13/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361851 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL4075908 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL14152581 | 0.83 | DGAT1 (0.48) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL19529547 | 0.79 | PDK1 (0.37) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL27673892 | 0.79 | PDK1 (0.35) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL31058002 | 0.78 | — | — | |
| SCHEMBL28035795 | 0.78 | — | — | |
| SCHEMBL11034219 | 0.76 | DGAT1 (0.42) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL12761004 | 0.76 | DGAT1 (0.42) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL776194 | 0.76 | DGAT1 (0.42) | ALDH1A1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294512-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-09-05 | — | — | US | disclosed |
| EP-4347033-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117858875-A | Hydroxy-and (halo) alkoxy-substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2022256842-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294512-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, NHERF1, HCN4 | ALDH1A1 559/4885PDK1 3606/4885PDK2 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.